Search

Your search keyword '"Indini, Alice"' showing total 45 results
Start Over Author "Indini, Alice" Search Limiters Available in Library Collection
45 results on '"Indini, Alice"'

3. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center

Author

Denaro, Nerina, primary, Passoni, Emanuela, additional, Indini, Alice, additional, Nazzaro, Gianluca, additional, Beltramini, Giada Anna, additional, Benzecry, Valentina, additional, Colombo, Giuseppe, additional, Cauchi, Carolina, additional, Solinas, Cinzia, additional, Scartozzi, Mario, additional, Marzano, Angelo Valerio, additional, and Garrone, Ornella, additional

Published
2023
Full Text
View/download PDF

4. Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study

Author

Cantini, Luca, primary, Paoloni, Francesco, additional, Pecci, Federica, additional, Spagnolo, Francesco, additional, Genova, Carlo, additional, Tanda, Enrica Teresa, additional, Aerts, Sophie, additional, Rebuzzi, Sara Elena, additional, Fornarini, Giuseppe, additional, Zoratto, Federica, additional, Fancelli, Sara, additional, Lupi, Alessio, additional, Della Corte, Carminia Maria, additional, Parisi, Alessandro, additional, Bennati, Chiara, additional, Ortega, Cinzia, additional, Atzori, Francesco, additional, Piovano, Pier Luigi, additional, Orciuolo, Corrado, additional, De Tursi, Michele, additional, Ghidini, Michele, additional, Botticelli, Andrea, additional, Scagnoli, Simone, additional, Belluomini, Lorenzo, additional, Leporati, Rita, additional, Veccia, Antonello, additional, Di Giacomo, Anna Maria, additional, Festino, Lucia, additional, Cortinovis, Diego, additional, Acquati, Mirko, additional, Filetti, Marco, additional, Giusti, Raffaele, additional, Tucci, Marco, additional, Sergi, Maria Chiara, additional, Garutti, Mattia, additional, Puglisi, Fabio, additional, Manglaviti, Sara, additional, Citarella, Fabrizio, additional, Santoni, Matteo, additional, Rijavec, Erika, additional, Lo Russo, Giuseppe, additional, Santini, Daniele, additional, Addeo, Alfredo, additional, Antonuzzo, Lorenzo, additional, Indini, Alice, additional, Rocchi, Marco Bruno Luigi, additional, Cortellini, Alessio, additional, Grossi, Francesco, additional, Ascierto, Paolo Antonio, additional, Aerts, Joachim G J V, additional, and Berardi, Rossana, additional

Published
2023
Full Text
View/download PDF

5. Safety of extended interval dosing immune checkpoint inhibitors:a multicenter cohort study

Author

Cantini, Luca, Paoloni, Francesco, Pecci, Federica, Spagnolo, Francesco, Genova, Carlo, Tanda, Enrica Teresa, Aerts, Sophie, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Zoratto, Federica, Fancelli, Sara, Lupi, Alessio, Della Corte, Carminia Maria, Parisi, Alessandro, Bennati, Chiara, Ortega, Cinzia, Atzori, Francesco, Piovano, Pier Luigi, Orciuolo, Corrado, De Tursi, Michele, Ghidini, Michele, Botticelli, Andrea, Scagnoli, Simone, Belluomini, Lorenzo, Leporati, Rita, Veccia, Antonello, Di Giacomo, Anna Maria, Festino, Lucia, Cortinovis, Diego, Acquati, Mirko, Filetti, Marco, Giusti, Raffaele, Tucci, Marco, Sergi, Maria Chiara, Garutti, Mattia, Puglisi, Fabio, Manglaviti, Sara, Citarella, Fabrizio, Santoni, Matteo, Rijavec, Erika, Lo Russo, Giuseppe, Santini, Daniele, Addeo, Alfredo, Antonuzzo, Lorenzo, Indini, Alice, Rocchi, Marco Bruno Luigi, Cortellini, Alessio, Grossi, Francesco, Ascierto, Paolo Antonio, Aerts, Joachim G.J.V., Berardi, Rossana, Cantini, Luca, Paoloni, Francesco, Pecci, Federica, Spagnolo, Francesco, Genova, Carlo, Tanda, Enrica Teresa, Aerts, Sophie, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Zoratto, Federica, Fancelli, Sara, Lupi, Alessio, Della Corte, Carminia Maria, Parisi, Alessandro, Bennati, Chiara, Ortega, Cinzia, Atzori, Francesco, Piovano, Pier Luigi, Orciuolo, Corrado, De Tursi, Michele, Ghidini, Michele, Botticelli, Andrea, Scagnoli, Simone, Belluomini, Lorenzo, Leporati, Rita, Veccia, Antonello, Di Giacomo, Anna Maria, Festino, Lucia, Cortinovis, Diego, Acquati, Mirko, Filetti, Marco, Giusti, Raffaele, Tucci, Marco, Sergi, Maria Chiara, Garutti, Mattia, Puglisi, Fabio, Manglaviti, Sara, Citarella, Fabrizio, Santoni, Matteo, Rijavec, Erika, Lo Russo, Giuseppe, Santini, Daniele, Addeo, Alfredo, Antonuzzo, Lorenzo, Indini, Alice, Rocchi, Marco Bruno Luigi, Cortellini, Alessio, Grossi, Francesco, Ascierto, Paolo Antonio, Aerts, Joachim G.J.V., and Berardi, Rossana

Abstract

BACKGROUND: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. METHODS: Characteristics of 812 consecutive solid cancer patients who received at least 1 cycle of ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 mg Q4W) after switching from canonical interval dosing (CD; pembrolizumab 200 mg Q3W or nivolumab 240 mg Q2W) or treated upfront with ED were retrieved. The primary objective was to compare irAEs patterns within the same population (before and after switch to ED). irAEs spectrum in patients treated upfront with ED and association between irAEs and overall survival were also described. RESULTS: A total of 550 (68%) patients started ICIs with CD and switched to ED. During CD, 225 (41%) patients developed any grade and 17 (3%) G3 or G4 irAEs; after switching to ED, any grade and G3 or G4 irAEs were experienced by 155 (36%) and 20 (5%) patients. Switching to ED was associated with a lower probability of any grade irAEs (adjusted odds ratio [aOR] = 0.83, 95% confidence interval [CI] = 0.64 to 0.99; P = .047), whereas no difference for G3 or G4 events was noted (aOR = 1.55, 95% CI = 0.81 to 2.94; P = .18). Among patients who started upfront with ED (n = 232, 32%), 107 (41%) developed any grade and 14 (5%) G3 or G4 irAEs during ED. Patients with irAEs during ED had improved overall survival (adjusted hazard ratio [aHR] = 0.53, 95% CI = 0.34 to 0.82; P = .004 after switching; aHR = 0.57, 95% CI = 0.35 to 0.93; P = .025 upfront). CONCLUSIONS: Switching ICI treatment from CD and ED did not increase the incidence of irAEs and represents a safe option also outside clinical trials.

Published
2023

8. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies

Author

Petrelli, Fausto, primary, Ghidini, Antonio, additional, Ghidini, Michele, additional, Bukovec, Roberta, additional, Trevisan, Francesca, additional, Turati, Luca, additional, Indini, Alice, additional, Seghezzi, Silvia, additional, Lonati, Veronica, additional, Moleri, Giovanna, additional, Tomasello, Gianluca, additional, and Zaniboni, Alberto, additional

Published
2022
Full Text
View/download PDF

9. Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib

Author

Rijavec,Erika, Biello,Federica, Indini,Alice, Grossi,Francesco, Genova,Carlo, Rijavec,Erika, Biello,Federica, Indini,Alice, Grossi,Francesco, and Genova,Carlo

Abstract

Erika Rijavec,1 Federica Biello,2 Alice Indini,3 Francesco Grossi,3 Carlo Genova4,5 1Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 2Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; 3Division of Medical Oncology, University of Insubria, ASST dei Sette Laghi, Varese, Italy; 4UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 5Department of Internal Medicine and Medical Specialties (DIMI), Università degli Studi di Genova, Genova, ItalyCorrespondence: Erika Rijavec, Email ery80x@yahoo.itAbstract: Rearrangement of anaplastic lymphoma kinase (ALK) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a few years due to acquired resistance. Brigatinib is a second-generation ALK inhibitor effective in presence of several ALK mutations with demonstrated activity against central nervous system metastases. Currently, brigatinib is approved to treat ALK-positive metastatic NSCLC patients not previously treated with ALK inhibitors and patients who have progressed on or are intolerant to crizotinib. In this review, we provide a summary of results from clinical trials involving brigatinib, and we discuss its possible role in the management of ALK-positive NSCLC in the following years.Keywords: brigatinib, non-small cell lung cancer, anaplastic lymphoma kinase

Published
2022

12. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies

Author

Petrelli, Fausto, primary, Ghidini, Antonio, additional, Ghidini, Michele, additional, Bukovec, Roberta, additional, Trevisan, Francesca, additional, Turati, Luca, additional, Indini, Alice, additional, Seghezzi, Silvia, additional, Lonati, Veronica, additional, Moleri, Giovanna, additional, Tomasello, Gianluca, additional, and Zaniboni, Alberto, additional

Published
2021
Full Text
View/download PDF

21. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Author

Indini, Alice, primary, Nigro, Olga, additional, Lengyel, Csongor György, additional, Ghidini, Michele, additional, Petrillo, Angelica, additional, Lopez, Salvatore, additional, Raspagliesi, Francesco, additional, Trapani, Dario, additional, Khakoo, Shelize, additional, and Bogani, Giorgio, additional

Published
2021
Full Text
View/download PDF

22. Association of Obesity With Survival Outcomes in Patients With Cancer

Author

Petrelli, Fausto, primary, Cortellini, Alessio, additional, Indini, Alice, additional, Tomasello, Gianluca, additional, Ghidini, Michele, additional, Nigro, Olga, additional, Salati, Massimiliano, additional, Dottorini, Lorenzo, additional, Iaculli, Alessandro, additional, Varricchio, Antonio, additional, Rampulla, Valentina, additional, Barni, Sandro, additional, Cabiddu, Mary, additional, Bossi, Antonio, additional, Ghidini, Antonio, additional, and Zaniboni, Alberto, additional

Published
2021
Full Text
View/download PDF

25. Developing a risk assessment score for cancer patients during COVID-19 pandemic

Author

Indini, Alice, Rijavec, Erika, Ghidini, Michele, Cattaneo, Monica, and Grossi, Francesco

Subjects
Oncology, viruses, coronavirus, cancer, COVID-19, Immunotherapy, Article, infection, respiratory tract diseases
Abstract

The novel coronavirus (CoV) pandemic is a serious threat for cancer patients, who have an immunocompromised status, and are considered at high risk for infections. Data on the novel CoV respiratory disease (COVID-19) in cancer patients are still limited. Unlike other common viruses, CoV have not shown to cause a more severe disease in immunocompromised subjects. Along with direct viral pathogenicity, in some individuals CoV infection triggers an uncontrolled aberrant inflammatory response, leading to lung tissue damage. In cancer patients treated with immunotherapy (e.g. immune-checkpoint inhibitors), COVID-19 may therefore represent a serious threat. After a thorough review of the literature on CoV pathogenesis and cancer, we selected several shared features to define which patients can be considered at higher risk for COVID-19. We combined these clinical and laboratory variables, with the aim of developing a score to weight the risk of COVID-19 in cancer patients., Highlights • There is limited data on the novel coronavirus disease (COVID-19) in cancer patients. • COVID-19 in cancer patients seems as contagious as for the general population. • Immunesuppression might not be an additional risk factor for coronavirus infection. • The pathogenicity of COVID-19 is exacerbated by the host’s immune system. • Anticancer immunotherapy may contribute to an aberrant response in case of infection.

Published
2020

26. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Author

Rutkowski, Piotr, primary, Indini, Alice, additional, De Luca, Matilde, additional, Merelli, Barbara, additional, Mariuk-Jarema, Anna, additional, Teterycz, Pawel, additional, Rogala, Pawel, additional, Lugowska, Iwona, additional, Cybulska-Stopa, Bożena, additional, Labianca, Alice, additional, Di Guardo, Lorenza, additional, Del Vecchio, Michele, additional, Pigozzo, Jacopo, additional, Randon, Giovanni, additional, Corti, Francesca, additional, Tondini, Carlo Alberto, additional, Rulli, Eliana, additional, and Mandala, Mario, additional

Published
2020
Full Text
View/download PDF

27. Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy

Author

Teterycz, Pawel, primary, Czarnecka, Anna M., additional, Indini, Alice, additional, Spałek, Mateusz J., additional, Labianca, Alice, additional, Rogala, Pawel, additional, Cybulska-Stopa, Bożena, additional, Quaglino, Pietro, additional, Ricardi, Umberto, additional, Badellino, Serena, additional, Szumera-Ciećkiewicz, Anna, additional, Falkowski, Slawomir, additional, Mandala, Mario, additional, and Rutkowski, Piotr, additional

Published
2020
Full Text
View/download PDF

28. An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival

Author

Mannavola, Francesco, primary, Mandala, Mario, additional, Todisco, Annalisa, additional, Sileni, Vanna Chiarion, additional, Palla, Marco, additional, Minisini, Alessandro Marco, additional, Pala, Laura, additional, Morgese, Francesca, additional, Di Guardo, Lorenza, additional, Stucci, Luigia Stefania, additional, Guida, Michele, additional, Indini, Alice, additional, Quaglino, Pietro, additional, Ferraresi, Virginia, additional, Marconcini, Riccardo, additional, Tronconi, Maria Chiara, additional, Rossi, Ernesto, additional, Nigro, Olga, additional, Occelli, Marcella, additional, Cortellini, Alessio, additional, Quadrini, Silvia, additional, Palmieri, Giuseppe, additional, Pigozzo, Jacopo, additional, Ascierto, Paolo Antonio, additional, Vitale, Maria Grazia, additional, Strippoli, Sabino, additional, Ferrucci, Pier Francesco, additional, Berardi, Rossana, additional, Randon, Giovanni, additional, Cardone, Pietro, additional, Schinzari, Giovanni, additional, Silvestris, Franco, additional, and Tucci, Marco, additional

Published
2020
Full Text
View/download PDF

29. A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic

Author

Zaniboni, Alberto, primary, Ghidini, Michele, additional, Grossi, Francesco, additional, Indini, Alice, additional, Trevisan, Francesca, additional, Iaculli, Alessandro, additional, Dottorini, Lorenzo, additional, Moleri, Giovanna, additional, Russo, Alessandro, additional, Vavassori, Ivano, additional, Brevi, Alessandra, additional, Rausa, Emanuele, additional, Boni, Luigi, additional, Dondossola, Daniele, additional, Valeri, Nicola, additional, Ghidini, Antonio, additional, Tomasello, Gianluca, additional, and Petrelli, Fausto, additional

Published
2020
Full Text
View/download PDF

32. Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Author

Parisi, Alessandro, primary, Cortellini, Alessio, additional, Cannita, Katia, additional, Venditti, Olga, additional, Camarda, Floriana, additional, Calegari, Maria Alessandra, additional, Salvatore, Lisa, additional, Tortora, Giampaolo, additional, Rossini, Daniele, additional, Germani, Marco Maria, additional, Boccaccino, Alessandra, additional, Dell’Aquila, Emanuela, additional, Fulgenzi, Claudia, additional, Santini, Daniele, additional, De Tursi, Michele, additional, Tinari, Nicola, additional, Di Marino, Pietro, additional, Lombardi, Pasquale, additional, Roselló Keränen, Susana, additional, Huerta Álvaro, Marisol, additional, Zurlo, Ina Valeria, additional, Corsi, Domenico Cristiano, additional, Emiliani, Alessandra, additional, Zanaletti, Nicoletta, additional, Troiani, Teresa, additional, Vitale, Pasquale, additional, Giampieri, Riccardo, additional, Merloni, Filippo, additional, Occhipinti, Mario Alberto, additional, Marchetti, Paolo, additional, Roberto, Michela, additional, Mazzuca, Federica, additional, Ghidini, Michele, additional, Indini, Alice, additional, Garajova, Ingrid, additional, Zoratto, Federica, additional, Delle Monache, Simona, additional, Porzio, Giampiero, additional, and Ficorella, Corrado, additional

Published
2020
Full Text
View/download PDF

37. Investigating the role of immunotherapy in advanced/ recurrent female genital tract melanoma: a preliminary experience.

Author

Indini, Alice, Guardo, Lorenza Di, Cimminiello, Carolina, Lorusso, Domenica, Raspagliesi, Francesco, and Vecchio, Michele Del

Subjects
*GENITALIA, *MELANOMA, *CERVIX uteri, *IMMUNOTHERAPY, *GENITALIA infections, *LOG-rank test
Abstract

Objective: immunotherapy with immune checkpoint inhibitors has become one of the standard therapeutic modalities for patients with advanced melanoma. Melanoma of the female lower genital tract is a rare and aggressive disease, with poor long-term clinical outcomes. To date, no study evaluated the role of immunotherapy in metastatic melanoma of the lower genital tract. Methods: Data of women with metastatic melanoma of the lower genital tract were prospectively collected. Survival outcomes over time was assessed using Kaplan-Meier model. Results: Seven cases of metastatic melanoma of the lower genital tract (vulva [n=2], vagina [n=4], and uterine cervix [n=1]) treated with immune checkpoint inhibitors are reviewed. Two patients had metastatic disease at diagnosis, while 5 patients developed metastatic disease at a mean (standard deviation) time of 9.9 (±3.0) months from primary diagnosis. Four patients received an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA4) (ipilimumab) and 3 received an anti-programmed cell death 1 (PD-1) (pembrolizumab [n=2], nivolumab [n=1]) therapy. The response rate to immunotherapy was 28.5%. Patients receiving an anti-PD-1 experienced a better progression-free survival than patients treated with anti-CTLA4 (p=0.01, log-rank test). Although not reaching statistical significance, overall survival was better in patients having an anti-PD-1 therapy in comparison to anti- CTLA4 (p=0.15, log-rank test). Conclusion: Results from our series confirm the poor prognosis of women with metastatic melanoma of the lower genital tract, thus supporting the need of exploring new treatment modalities. Further studies are warranted to improve knowledge on the role of immunotherapy in metastatic melanoma of the lower genital tract. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

38. Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies

Author

Cona, Maria Silvia, primary, Torri, Valter, additional, Di Nicola, Massimo, additional, Garassino, Marina, additional, Del Vecchio, Michele, additional, Cresta, Sara, additional, Signorelli, Diego, additional, Damian, Silvia, additional, Duca, Matteo, additional, Indini, Alice, additional, Niger, Monica, additional, and de Braud, Filippo, additional

Published
2016
Full Text
View/download PDF

42. EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

Author

Antonicelli, Alberto, primary, Cafarotti, Stefano, additional, Indini, Alice, additional, Galli, Alessio, additional, Russo, Andrea, additional, Cesario, Alfredo, additional, Lococo, Filippo Maria, additional, Russo, Patrizia, additional, Mainini, Alberto Franco, additional, Bonifati, Luca Giuseppe, additional, Nosotti, Mario, additional, Santambrogio, Luigi, additional, Margaritora, Stefano, additional, Granone, Pierluigi Maria, additional, and Dutly, André Emanuel, additional

Published
2013
Full Text
View/download PDF

43. Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review.

Author

Indini, Alice, Roila, Fausto, Grossi, Francesco, Massi, Daniela, and Mandalà, Mario

Subjects
*IMMUNE checkpoint inhibitors, *BRAF genes, *PROTEIN-tyrosine kinase inhibitors, *DELETION mutation, *MELANOMA
Abstract

Mucosal melanoma is a rare and aggressive subtype of melanoma. Unlike its cutaneous counterpart, mucosal melanoma has only gained limited benefit from novel treatment approaches due to the lack of actionable driver mutations and poor response to immunotherapy. Over the last years, whole-genome and exome sequencing techniques have led to increased knowledge on the molecular landscape of mucosal melanoma. Molecular studies have underlined noteworthy findings with potential therapeutic implications, including the presence of KIT mutations, which are potential targets of tyrosine kinase inhibitors currently in use in the clinic (imatinib), but also SF3B1 mutation, CDK4 amplifications, and CDKN2A gene deletions, which are presently under investigation in clinical trials. Recent results from a pooled analysis of patients with mucosal melanoma treated with immunotherapy have suggested that the combination of immune checkpoint inhibitors might improve survival outcomes in this subset of patients, as compared with single-agent immunotherapy. However, these results are not confirmed across different studies, and combo-immunotherapy correlates with a higher rate of adverse events. In this review, we describe the clinical, biological, and genetic features of mucosal melanoma. We also provide an update on the results of approved systemic treatment in this setting and overview the therapeutic strategies currently under investigation in clinical trials. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.

Author

Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, and Berardi R

Subjects
Humans, Nivolumab adverse effects, Immune Checkpoint Inhibitors therapeutic use, Retrospective Studies, Antineoplastic Agents, Immunological adverse effects, Neoplasms
Abstract

Background: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown., Methods: Characteristics of 812 consecutive solid cancer patients who received at least 1 cycle of ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 mg Q4W) after switching from canonical interval dosing (CD; pembrolizumab 200 mg Q3W or nivolumab 240 mg Q2W) or treated upfront with ED were retrieved. The primary objective was to compare irAEs patterns within the same population (before and after switch to ED). irAEs spectrum in patients treated upfront with ED and association between irAEs and overall survival were also described., Results: A total of 550 (68%) patients started ICIs with CD and switched to ED. During CD, 225 (41%) patients developed any grade and 17 (3%) G3 or G4 irAEs; after switching to ED, any grade and G3 or G4 irAEs were experienced by 155 (36%) and 20 (5%) patients. Switching to ED was associated with a lower probability of any grade irAEs (adjusted odds ratio [aOR] = 0.83, 95% confidence interval [CI] = 0.64 to 0.99; P = .047), whereas no difference for G3 or G4 events was noted (aOR = 1.55, 95% CI = 0.81 to 2.94; P = .18). Among patients who started upfront with ED (n = 232, 32%), 107 (41%) developed any grade and 14 (5%) G3 or G4 irAEs during ED. Patients with irAEs during ED had improved overall survival (adjusted hazard ratio [aHR] = 0.53, 95% CI = 0.34 to 0.82; P = .004 after switching; aHR = 0.57, 95% CI = 0.35 to 0.93; P = .025 upfront)., Conclusions: Switching ICI treatment from CD and ED did not increase the incidence of irAEs and represents a safe option also outside clinical trials., (© The Author(s) 2023. Published by Oxford University Press.)

Published
2023
Full Text
View/download PDF

45. Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.

Author

Rijavec E, Biello F, Indini A, Grossi F, and Genova C

Abstract

Rearrangement of anaplastic lymphoma kinase ( ALK ) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a few years due to acquired resistance. Brigatinib is a second-generation ALK inhibitor effective in presence of several ALK mutations with demonstrated activity against central nervous system metastases. Currently, brigatinib is approved to treat ALK-positive metastatic NSCLC patients not previously treated with ALK inhibitors and patients who have progressed on or are intolerant to crizotinib. In this review, we provide a summary of results from clinical trials involving brigatinib, and we discuss its possible role in the management of ALK-positive NSCLC in the following years., Competing Interests: Dr Erika Rijavec reports personal fees from BRISTOL-MYERS SQUIBB, outside the submitted work. Professor Francesco Grossi reports grants, personal fees from Bristol Myers Squibb, personal fees from Merck Sharp and Dome, personal fees from Eli-Lilly, personal fees from Amgen, personal fees from Sanofi, personal fees from Novartis, personal fees from Astra Zeneca, personal fees from Roche, personal fees from Pierre Fabre, personal fees from Celgene, personal fees from Takeda, personal fees from Boehringer, personal fees from Merck, during the conduct of the study. Dr Carlo Genova reports personal fees from Astra Zeneca, personal fees from Boehringer Ingelheim, grants from Bristol Myers Squibb, personal fees from Merck Sharp & Dohme, personal fees from Roche, personal fees from Takeda, personal fees from ThermoFisher, grants from Italian Ministry of Health, outside the submitted work. The authors report no other conflicts of interest in this work., (© 2022 Rijavec et al.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results